Clinical trials: Sclerosing Cholangitis
Primary Sclerosing Cholangitis
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible…
- Trial name
- VISTAS (NCT04663308)
- Testing
- Volixibat
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 182 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to…
- Trial name
- NCT06553768
- Testing
- Maralixibat
- Where
- 23 sites in United States, Brazil and 8 more
- Volunteers
- 90 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis.
- Conditions
- Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), Pediatric Inflammatory Bowel Diseases
- Trial name
- VERDA (NCT07646223)
- Testing
- Oral Vancomycin
- Where
- Finland
- Volunteers
- 140 people
- Sponsor
- Tampere University Hospital
Autoimmune Hepatitis, Primary Biliary Cholangitis (PBC)
Deciphering the Self-antigen Specific T Cell Signature of Autoimmune Liver Diseases
The study aims to establish the molecular signature of autoimmune self-antigen-specific T cells in AutoImmune Liver Disease (AILD)
- Conditions
- Autoimmune Hepatitis, Primary Biliary Cholangitis (PBC), Autoimmune Liver Disease, Primary Sclerosing Cholangitis (PSC)
- Trial name
- DISTAL (NCT07784881)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Nantes University Hospital
Autoimmune Liver Disease, Primary Sclerosing Cholangitis
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Trial name
- NCT03175471
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Autoimmune Liver Disease, Autoimmune Hepatitis
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- NCT03178630
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD).
- Trial name
- ALINK (NCT05750498)
- Testing
- No interventions
- Where
- 8 sites in United States
- Volunteers
- 800 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Primary Sclerosing Cholangitis, Cholangitis
A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.
- Conditions
- Primary Sclerosing Cholangitis, Cholangitis, Cholangitis, Sclerosing, Bile Duct Diseases
- Trial name
- NCT03678480
- Testing
- HTD1801, Ursodeoxycholic Acid
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Primary Sclerosing Cholangitis, Liver Diseases
Primary Sclerosing Cholangitis in Children
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine.
- Conditions
- Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
- Trial name
- NCT04181138
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Arbor Research Collaborative for Health
Primary Sclerosing Cholangitis
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC.
- Trial name
- SHIP (NCT03561584)
- Testing
- Sulfasalazine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Brigham and Women's Hospital
Cholangitis, Sclerosing, PSC
Swiss Primary Sclerosing Cholangitis Cohort Study
Research project in which biological material is sampled and health-related personal data is further used and collected. Coded data are used.
- Conditions
- Cholangitis, Sclerosing, PSC, Primary Sclerosing Cholangitis (PSC)
- Trial name
- NCT03146936
- Where
- 21 sites in Switzerland
- Volunteers
- 120 people
- Sponsor
- Fondazione Epatocentro Ticino
Primary Sclerosing Cholangitis (PSC)
Genomics of Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC) is a progressive liver disorder of unknown cause. Current evidence suggests that genes, the genetic material we inherit from our parents, in combination with environmental factors, likely play…
- Trial name
- NCT01161992
- Testing
- Genetic Analysis
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Mayo Clinic
Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder
Vancomycin in Primary Sclerosing Cholangitis in Italy
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications.
- Conditions
- Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder, IBD
- Trial name
- VanC-IT (NCT05876182)
- Testing
- Oral Vancomycin
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- University of Milano Bicocca
Primary Sclerosing Cholangitis
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).
- Trial name
- HAAPS (NCT05295680)
- Testing
- Hymecromone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aparna Goel
Primary Sclerosing Cholangitis, Elastography
Disease Status in Primary Sclerosing Cholangitis by Elastography
Primary sclerosing cholangitis (PSC) is a chronic liver disease that can lead to liver cirrhosis, liver failure and liver cancer.
- Conditions
- Primary Sclerosing Cholangitis, Elastography, Hepatic Fibrosis, Magnetic Resonance Imaging
- Trial name
- NCT02446665
- Testing
- MR Elastography (MRE) and FibroScan
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto
Primary Sclerosing Cholangitis
norUrsodeoxycholic Acid vs Placebo in PSC
Double-blind, randomized, multi-center, placebo-controlled, comparative, phase III trial. The study will be conducted with two treatment groups in the form of a parallel group comparison and will serve to compare oral treatment…
- Trial name
- NCT03872921
- Testing
- norUrsodeoxycholic Acid
- Where
- 2 sites in Austria, Germany
- Volunteers
- 303 people
- Sponsor
- Dr. Falk Pharma GmbH
Primary Sclerosing Cholangitis
National Database on Primary Sclerosing Cholangitis (PSC)
Primary sclerosing cholangitis (PSC) a rare, chronic fibroinflammatory disease of the liver. No data about the disease epidemiology exist in Italy.
- Trial name
- NCT05618145
- Testing
- Clinical information
- Where
- 63 sites in Italy
- Volunteers
- 6,000 people
- Sponsor
- University of Milano Bicocca
Primary Sclerosing Cholangitis
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
The objective of this study is to evaluate the improvement of bile duct strictures following the administration of HK-660S in patients with Primary Sclerosing Cholangitis(PSC).
- Trial name
- NCT05866809
- Testing
- HK-660S
- Where
- 4 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- CuromeBiosciences
Primary Sclerosing Cholangitis
PSC Clinical Epidemiology in China
Primary sclerosing cholangitis (PSC) is a rare disease but is increasingly reported in China (mainly in the Chinese language). However, most of the PSC literatures reported from China are case reports, small case series, and…
- Trial name
- NCT04981756
- Testing
- observation
- Where
- 3 sites in China
- Volunteers
- 800 people
- Sponsor
- Beijing Friendship Hospital
Primary Sclerosing Cholangitis, Autoimmune Hepatitis
"Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children"
Based upon the possible implication of microbiota and abnormal microbial metabolites such as altered bile acids, in the pathogenesis of PSC, emerging data suggests that oral antibiotics, such as vancomycin and metronidazole, may…
- Conditions
- Primary Sclerosing Cholangitis, Autoimmune Hepatitis, Overlap Syndrome
- Trial name
- NCT03069976
- Testing
- Metronidazole
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain